The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars

U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars

May 23, 2017 • By Ben Hirschler

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LONDON (Reuters)—Britain’s competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade (infliximab) that it said was designed to restrict competition from so-called biosimilar copies.

You Might Also Like
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Biosimilars to Raise Unique Questions

The Competition and Markets Authority (CMA) says it had provisionally found the U.S. company’s European unit, Merck Sharp & Dohme (MSD), had abused its dominant position through the scheme, opening it up to potential financial penalties.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

MSD says it did not believe it had broken competition rules.

Infliximab is used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The drug is proving an important test for the emerging biosimilars industry. It was the first antibody drug for which copycat versions were approved by European regulators, leading to the launch of discounted products from biosimilar drugmakers, including South Korea’s Celltrion, which works with Pfizer.

One person familiar with the investigation says MSD offered a discount to customers who continued to buy Remicade in the same quantities, but not if they started buying biosimilars, which amounted to an incentive not to switch.

Remicade has been a big seller for Merck over the years, but sales have been falling in the face of biosimilar competition, declining 29% last year to $1.27 billion. Merck sells the drug in Europe, while Johnson & Johnson markets it in the U.S.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Such biotech drugs are made inside living cells so it is impossible to make exact generic copies. Instead, regulators have come up with the notion of approving products that are “similar” enough to do the same job.

Manufacturing and developing biosimilars requires considerable expertise and is relatively costly, but the field is attracting growing investment as multiple blockbuster biotech medicines start to go off patent.

Cancer Drugs Next
This year has seen the launch in Europe of the first biosimilar copy of an antibody drug for cancer, opening up a major new disease area to cut-price competition.

The CMA, which opened its investigation in December 2015, says it proposed to find MSD and its parent Merck & Co jointly and severally liable for the alleged infringement.

The competition regulator can fine companies up to 10% of their global turnover if they are found to have breached competition law, although a CMA spokesman emphasizes this was a ceiling rather than a guideline for penalties.

MSD says it was cooperating fully with the CMA, adding it was confident the proceedings would show it had complied with the law.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, infliximab, International, Legal, Merck & Co, Remicade, REMICADE (infliximab), U.K.

You Might Also Like:
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Biosimilars to Raise Unique Questions
  • As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.